Recent Posts
- Elios Therapeutics Announces the Appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors
- Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis – Society for Immunotherapy of Cancer
- Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial
- Elios Strengthens Board of Directors with Appointment of Key Financial Executive Michael Caprio
Recent Comments
No comments to show.